Through in silico evaluation, synthesis, binding affinity determination, and in vitro analysis, we identified two new VHL‐based PROTACs (2 and 9), which showed remarkable degradation of the protein of interest and antiproliferative activity in acute myeloid leukemia (AML) cells. Here, VHL is linked to acute myeloid leukemia.